The global gene therapy in CNS disorder market is poised for unprecedented growth, with market valuation anticipated to skyrocket from USD 8.2 billion in 2023 to USD 113.04 billion by 2033, registering a robust compound annual growth rate (CAGR) of 30% during the forecast period. This remarkable growth trajectory reflects increasing advancements and demand for cutting-edge therapeutic interventions for neurological conditions.
Historical Market Insights:
In the historical period from 2018 to 2022, the market for gene therapy in CNS disorders demonstrated steady progress, achieving a CAGR of 19%. This growth was fueled by heightened R&D investments, innovative technological applications, and a burgeoning awareness of the transformative potential of gene therapy in treating debilitating neurological conditions.
Driving Forces Behind the Growth:
The exponential rise in the gene therapy market can be attributed to:
- Innovative Advancements: Emerging technologies, such as CRISPR and viral vector delivery systems, are revolutionizing therapeutic efficacy and precision.
- Rising Prevalence of CNS Disorders: Conditions like Alzheimer’s, Parkinson’s, Huntington’s disease, and ALS drive demand for novel treatment options.
- Increased Investment in R&D: Pharmaceutical giants and biotechnological firms are channeling resources into gene therapy solutions, paving the way for breakthrough developments.
Forecast for the Future:
Over the next decade, the market is expected to witness widespread adoption as regulatory frameworks become more streamlined and access to advanced therapies broadens. Furthermore, collaborations between academic institutions, biotech companies, and healthcare providers are likely to accelerate innovation and bring transformative treatments closer to patients.
Industry Implications:
The projected growth underscores the transformative impact gene therapy is expected to have on the management and treatment of CNS disorders. It highlights the shift toward precision medicine and a future where chronic and life-altering neurological conditions could be mitigated effectively.
As the global healthcare landscape embraces this transformative wave, stakeholders across the pharmaceutical, healthcare, and biotech industries are presented with unparalleled opportunities to shape the future of neurological care.
Interest in Market Trends: Get Detailed Analysis and Insights with Our Comprehensive Report!
Key Takeaways from the Market Study:
- From 2018 to 2022, the Gene Therapy in CNS Disorder market grew at a CAGR of 19%.
- The global Gene Therapy in CNS Disorder market is expected to grow with a 30% CAGR during 2023 to 2033.
- As of 2033, the Gene Therapy in CNS Disorder Market is expected to reach USD 113.04 Billion.
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 40% market share for the Gene Therapy in CNS Disorder market.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fuelling further clinical trials and research studies dedicated to discovering Gene Therapy in CNS Disorder.” says an FMI analyst
Market Competition:
Key players in the market include companies such as Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird bio, Inc., Biogen, Pfizer Inc., Rapa Therapeutics, BrainStorm Cell Therapeutics, Eli Lilly and Company, and UniQure Biopharma, along with healthcare providers and technology companies among other global players.
- In November 2022, A team of researchers at University College London (UCL) developed a novel gene therapy that offers promise in treating neurological and psychiatric disorders. The therapy targets overactive brain cells that are responsible for causing several brain diseases, including epilepsy, by reducing their excitability. By using DNA sequences that control gene expression, the therapy drives the production of molecules that prevent these overactive cells from firing, thereby curbing epileptic seizures. Notably, the technique selectively alters only overactive cells while sparing normally functioning cells.
In preclinical studies, the new treatment demonstrated a higher efficacy than previous gene therapies or anti-seizure drugs tested in the same model. The team observed an approximately 80% reduction in spontaneous seizures in epileptic mice treated with the therapy. Furthermore, the researchers believe that this gene therapy has the potential to treat other disorders where some brain cells are overactive, such as Parkinson’s disease.
Key Segments Profiled in the Gene Therapy in CNS Disorder Industry Survey
Indication:
- Alzheimer’s Disease
- Huntington’s Disease
- Parkinson’s Disease
- Batten Disease
Type:
- Ex Vivo
- In Vivo
End User:
- Hospitals
- Speciality Clinics
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube